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1. Introduction 
The processes of absorption (A), distribution (D), metabolism (M) and excretion (E) 
(collectively referred as ADME) determine the pharmacokinetics (PK) of a compound. Lack 
of optimum PK is one of the major reasons for compounds to fail in the clinic resulting in 
high attrition rates. In the beginning of 1990, 39% of the drugs failed in the clinic due to poor 
PK emphasizing its importance in drug development (Waterbeemd and Gifford, 2003). In 
1988, a study of the pharmaceutical companies in UK showed that non-optimal PK was one 
of the major reasons (~40%) for termination of drugs in development (Prentis et al., 1988). In 
the last two decades this number dropped to ~ 10% (Yengi et al., 2007).  The main reasons 
for this significant drop in the number of compounds failing for PK reasons can be 
attributed to the following: a) application of concepts of drug metabolism and PK to design 
compounds in medicinal chemistry programs (Smith et al., 1996); b) development of in vitro 
ADME assays that are predictive of in vivo behavior (PK) of drugs (Obach et al., 1997; 
Venkatakrishnan et al.,2003; Pelkonen and Raunio, 2005; Thompson,2000; Fagerholm, 2007); 
c) use of the Lipinski rule of 5 to design oral drugs (Lipinski, 2000); d) development of 
computer programs to predict the human PK parameters and profiles based on in vitro 
ADME properties of drugs  (Jamei et al., 2009); e) PK/PD correlation studies in preclinical 
setting and f) high throughput screening of ADME properties in in vitro and in vivo assays 
for hundreds of compounds in the lead identification to lead optimization stages of drug 
discovery. The consequence of all the above mentioned developments in ADME have 
resulted in the frontloading of non-drug like compounds early in drug discovery and 
ultimately reducing the attrition rates of compounds in the clinic.  
Histone acetylases (HATs) and Histone deacetylases (HDACs) are enzymes that carry out 
acetylation and deacetylation, respectively, of histone proteins (Minucci and Pelicci, 2006). 
Histone proteins form a complex with DNA called as nucleosomes, which are the structural 
units of chromatin. The interplay of HATs and HDACs activities regulate the structure of 
chromatin and control gene expression. The aberrant expression of HDACs has been linked 
to the pathogenesis of cancer (Minucci and Pelicci, 2006). Histone deacetylase inhibitors 
www.intechopen.com
 
Drug Development – A Case Study Based Insight into Modern Strategies 
 
102 
(HDACi) are an emerging class of therapeutic agents that induce tumor cell cytostasis, 
differentiation and apoptosis in various hematologic and solid malignancies (Mercurio et al., 
2010; Stimson et al., 2009). They are known to exert their anti-tumor activity by inhibiting 
the HDACs, which play an important role in controlling gene expression by chromatin 
remodeling, that affect cell cycle and survival pathways (Stimson et al., 2009). Inhibitors of 
histone deacetylases (HDACi) also show promising anti-inflammatory properties as 
demonstrated in a number of animal and cellular models of inflammatory diseases and for 
diabetes (Christensen et al., 2011). The HDACi Zolinza (Vorinostat/ Suberolyanilide 
hydroxamic acid [SAHA]) and Romidepsin (FK228) have been approved by the FDA 
(United States Food and Drug Administration) for the treatment of cutaneous T cell 
Lymphoma (CTCL) (Mann et al., 2007, Grant et al.,2010) and for peripheral T cell lymphoma 
(PTCL)(http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/022393s004ltr.p
df) as such demonstrating clinical “proof-of-principle” for this class of compounds.  
Four groups of HDAC inhibitors have been characterized: (i) short chain fatty acids (e.g., 
Sodium butyrate and phenylbutyrate), (ii) cyclic tetrapeptides (e.g., Depsipeptide and 
Trapoxin), (iii) benzamides (e.g. MGCD0103 (Mocetinostat), Cl-994 and MS-275 
(Entinostat)), and (iv) hydroxamic acids (e.g., SAHA [Vorinostat/Zolinza]), LBH589 
(Panabinostat), SB939 (Pracinostat), ITF2357 (Givinostat), PXD101 etc). Table 1 shows 
compounds that are currently in different stages of clinical development.  
The clinical progress that has been made by hydroxamic acid derivatives as HDAC 
inhibitors is of particular interest because they are usually considered as non-druggable and 
are down-prioritized in lead identification campaigns attributing to their poor 
physicochemical and ADME properties. SB939 (Pracinostat) is a potent HDACi that was 
discovered and developed at S*BIO (Wang et al., 2011; Novotny-Diermayr et al, 2011) to 
overcome some of the ADME and PK/PD (Pharmacokinetic/Pharmacodynamic) limitations 
of the current HDACi.  The pharmacokinetics and drug metabolism aspects of the four 
classes of HDACi have not been reviewed extensively. In this article, we review the 
pharmacokinetic and drug metabolism properties of SB939 and the preclinical and clinical 
ADME aspects of other HDAC inhibitors in the clinic. 
2. Short chain fatty acids  
2.1 Sodium butyrate (SB) 
Sodium butyrate is a short chain fatty acid inhibitor of HDAC enzymes that is in phase 2 
clinical trials. The PK of SB in preclinical species was characterized by poor bioavailability, 
short t1/2 (< 5 min in mice and rabbits), leading to challenges in oral administration 
(Coradini et al, 1999; Daniel P et al, 1989). Butyrate was found to be transported by via a 
carrier mediated transport system MCT1 in Caco-2 cells suggesting that the absorption of SB 
might be saturable (Stein et al., 2000). SB has been reported to significantly increase the 
cytochrome P450 3A4 (CYP3A4) activity in Caco-2 cells transfected with CYP3A4 (Cummins 
et al; 2001) and induce P glycoprotein (PgP) in vivo (Machavaram et al., 2000).  Due to its low 
potency very high doses were required to achieve pharmacological concentrations in 
animals and humans (Kim and Bae, 2011). In PK studies in mice and rats, SB showed rapid 
clearance (CL) with non-linear PK resulting from the high doses (up to 5 g/kg in mice), 
based on which the authors indicated that high doses would be problematic in humans 
(Egorin et al., 1999). In a clinical pharmacology study in leukemia patients, where SB was 
administered as continuous intravenous (IV) infusions (at a dose of 500 mg/kg/day) over a 
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Compound name Structure Class 
Stage of clinical 
development* 
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*Reference from http://www.fda.gov 
Table 1. HDAC inhibitors in clinical development 
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10 day period, SB declined rapidly post infusion with a very short t1/2 (~ 6 min), with high 
systemic clearance (CL~5 L/h/kg) and low volume of distribution (Vd =0.74 L/kg) (Miller et 
al., 1987). The amount of unchanged SB in urine was minimal suggesting that SB’s clearance 
was primarily by metabolism. The authors concluded that the lack of efficacy of SB in the 
leukemic patients was due to its low plasma levels and very short t1/2 (Miller et al., 1987). 
2.2 Sodium phenyl butyrate (PB) 
Sodium phenyl butyrate (PB) is an aromatic fatty acid HDACi, with low potency of 0.5 mM 
that is in phase 2 trials for cancer.  PB (Buphenyl) has already been approved by the FDA for 
patients with hyperammonemia (Gilbert et al., 2001). 
In a phase 1 study in patients with solid tumors, the PK of PB was characterized by rapid 
absorption (time of peak concentration [tmax] ~1.8 h), dose proportional increase in oral 
exposures between doses of 9 and 36 g/day, a short t1/2 of 1 h, with mean absolute oral 
bioavailability (F) of 78% (Gilbert et al., 2001). In the same study, the major circulating 
metabolites of PB were phenylacetate (PA) and phenyacetylglutamine (PG), the exposures of 
which were 46-66% and 70-100% respectively of PB, suggesting extensive metabolic clearance 
of PB in humans. The highest percentage of patients that showed stable disease was from the 
36 g/day cohort, in which the time above 0.5 mM was ~ 4.0 h (Gilbert et al., 2001). In another 
phase 1 study in patients with myelodysplastic syndrome (MDS) and acute myelogenous 
leukemia (AML), where PB was dosed as IV infusions, PB showed non-linear PK between 125 
and 500 mg/kg/day, with PA and PG being formed as major metabolites (Gore et al., 2001). 
The low potency of PB requires very high doses in humans, leading to non-linear kinetics, thus 
making it a less attractive chemotherapeutic agent. In another phase 1 study, where PB was 
evaluated as continuous IV infusions (120 h) in solid tumors, the PK of PB was best described 
by saturable elimination, and PG was the major metabolite found in urine which was 
indicative of extensive metabolic clearance of PB in humans (Carducci et al., 2001). In the same 
study the plasma clearance (CL) of PB increased during the infusion period in some patients at 
higher dose levels. In a dose escalation oral study of PB in patients with glioma, who also 
received anticonvulsants concomitantly, the mean CL of PB was significantly higher than in 
solid tumor patients, and the possible reason was attributed to the induction of cytochrome 
P450 (CYP450) enzymes by anticonvulsants (Phuphanich et al., 2005). Thus it appears that the 
CYP450 metabolism might play a significant role in clearance of PB in humans. 
2.3 Sodium valproate 
Sodium valproate is a short chain fatty acid that is currently in phase 1 and 2 clinical trials in 
patients with solid tumors and hematological malignancies (Federico and Bagella, 2011). 
Sodium valproate (Depakote) has been previously approved for use in epilepsy patients and 
is in medical use for the last 3 decades (Federico and Bagella, 2011). It is a moderately potent 
inhibitor of class 1 HDAC enzymes with promising antitumor effects in vitro and in vivo. The 
human ADME of sodium valproate is characterized by a) high plasma protein binding (PPB) 
of 90 % with concentration dependent PPB; b) weak inhibitor of some CYP450, epoxide 
hydrolase and glucoronosyl transferases; c) entirely metabolized by the liver via 
glucoronidation and β-oxidation pathways with less than 3% of unchanged parent drug 
found in the urine; d) minimum drug-drug interaction (DDI) potential with CYP450 
inhibitors as CYP450 mediated oxidation is a minor pathway ; e) high absolute oral 
bioavailability (90%); f) mean terminal half-life of 9-16 h (Depakote prescribing information, 
http://www.accessdata.fda.gov/drugsatfda_docs/label).  
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3. Cyclic tetrapeptides 
3.1 Romidepsin (FK228, depsipeptide, ISTODAX
TM
) 
Romidepsin is a bicyclic peptide that was isolated as a secondary metabolite from a 
naturally occurring soil bacterium, and found to be a potent anti-tumor agent in vitro and in 
vivo (Ueda et al., 1994) and subsequently found to be a potent HDACi. It was approved by 
the FDA for treatment of patients with refractory CTCL (Mercurio et al., 2010). Romidepsin 
is a high molecular weight drug (Mw ~ 541), highly lipophilic, and insoluble in water, 
necessitating intraperitoneal and subcutaneous administrations in pharmacology studies 
(Ueda et al., 1994). The in vitro PPB of Romidepsin to human plasma was 92-94 % over a 
concentration of 50-1000 ng/mL, indicating high binding (http://www.accessdata.fda). 
Romidepsin is a substrate of PgP and MRP1 (Xiao et al., 2005). Depsipeptide was extensively 
metabolized by human liver microsomes, leading to the formation of at least 10 different 
metabolites, and was found to be primarily metabolized by CYP3A4 in vitro (Shiraga et al., 
2005). Among the metabolites formed, mono-oxidation, di-oxidation, reduction of disulfide 
metabolites and two unidentified metabolites were the major metabolites in humans 
(http://www.accessdata.fda). It did not seem to inhibit any of the major human CYP450 
enzymes in vitro, and there are no reports on its effect on the induction of human CYP450s 
(http://www.accessdata.fda). The preclinical PK of depsipeptide was characterized by high 
systemic CL and long t1/2 (~ 6.0 h) in mice (Graham et al., 2006). In rats, the volume of 
distribution at steady state (Vss) was very high (100 L/kg) and systemic CL was high (~ 49 
L/h/kg), t1/2 was short (18 min), and had poor oral bioavailability (F= ~ 2-11%) (Li and 
Chan, 2000). The low F in rats may be could be due to high first-pass effect, poor solubility 
and PgP efflux. Systemic CL (~1.8 L/h/kg) and t1/2 (205 min) were moderate in nonhuman 
primates (Berg et al., 2004).  In a radiolabelled mass-balance study in rats with FK228, 
approximately 98% of the dose was recovered in excreta with ~ 79% of the dose in the feces, 
and biliary clearance appeared to be the main clearance mechanism 
(http://www.accessdata.fda; Shiraga et al., 2005). Unchanged FK228 accounted for 3% of 
the dose, with > 30 metabolites detected in bile, indicating extensive metabolism of FK228 
(Shiraga et al., 2005). The clinical PK of Romidepsin was characterized by low Vss (54 L), low 
CL (20 L/h), and a short t1/2 (~ 3.5 h) (http://www.accessdata.fda; Woo et al., 2009). The 
intra-patient variability was moderate to high (30-80%) and the inter-patient variability was 
high (50-70%) (http://www.accessdata.fda;). Despite the high inter-patient variability the 
AUC and Cmax increased dose proportionally (http://www.accessdata.fda). 
Romidepsin is the only HDACi that seems to be a PgP substrate. Romidepsin induced PgP 
expression in the HCT15 tumor cell line and conferred resistance to its action (Xiao et al., 
2005).  A possibility of correlation between PgP induction and the poor response rate of 
Romidepsin in cancer patients has been proposed (Xiao et al., 2005).  
4. Benzamides 
4.1 Mocetinostat (MGCD0103) 
Mocetinostat (MGCD0103), an aminophenyl benzamide, is a potent inhibitor of HDAC 1, 2, 
and 3 enzymes and has recently completed Phase 2 clinical trials (Mercurio et al., 2010). It is 
a small molecule (Mw~396) and moderately lipophilic (LogP=2.6). There is no information 
available on its permeability, microsomal stability, metabolism, plasma protein binding, 
CYP450 inhibition and induction. In preclinical PK studies in mice, rat and dog, 
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Mocetinostat showed moderate Vss (0.35 -0.91 L/kg), moderate to high CL (1.7 to 4.3 
L/h/kg), short t1/2 (0.6-1.3 h), with F ranging between low (mice =12%), moderate (rat=47%) 
and low-high (dogs=1-92%) (Zhou et al., 2008). In preclinical PK and PD studies, where the 
dihydrobromo salt of Mocetinostat was used, the dosing formulations required acidification 
and cosolvent addition indicating solubility issues (Zhou et al, 2008).  
In a phase 1 study in patients with leukemia, the oral PK of Mocetinostat was characterized 
by rapid absorption (tmax = 0.5-1.2 h),  mean elimination t1/2 of 7-11 h, and a dose related 
increase in peak plasma concentration (Cmax) and area under the concentration-time curve 
(AUC) between 20 and 60 mg/m2 and tended to plateau at higher doses (Garcia-Manero et 
al., 2011). Based on the lack of accumulation upon repeated dosing, it was suggested that 
induction or inhibition of drug elimination was unlikely in humans (Le Tourneau and Siu, 
2008). 
4.2 CI994 (N-acetyldinaline) 
CI994 (N-acetlydinaline), belonging to the benzamide class, is a HDACi with promising 
antitumor activities in preclinical xenograft models, and subsequently progressed to phase 1  
2 clinical trials (Richards et al., 2006). CI994, a small molecule (MW=269.3) and with poor 
aqueous solubility, was developed as an acetylated analogue of Dinaline (GOE-1734), which, 
also showed equivalent antitumor activity (LoRusso et al., 1996). CI994 was eventually 
identified as an active metabolite of Dinaline (LoRusso et al., 1996). Limited data is available 
on its in vitro ADME. It showed low PPB in mice (20%) (Foster et al., 1997). In an oral PK and 
metabolism study in mice, where CI-994 was dosed once daily at 50 mg/kg for 14 days, it 
showed moderately rapid absorption (tmax= 30-45 min), 2 compartment disposition with a 
terminal t1/2 on day 1 (9.4 h) being longer than on day 14 (3.4 h), and oral CL ranging 
between 0.42 (Day 1) -0.52 (day 14) ml/min (Foster et al., 1997). High amounts of unchanged 
drug (42-58% of dose) were found in the urine with minimal amounts in fecal samples, 
suggesting that renal clearance was a major clearance pathway for CI-994. Low amounts of 
Dinaline were found in urine and feces indicating that in vivo conversion of CI-994 to 
Dinaline were not significant. In rhesus monkeys, the PK of CI-994 was characterized by low 
volume of distribution (Vd) (0.3 L/kg) and CL (0.05 L/h/kg), a moderate t1/2 (7.4 h), and 
high brain penetration (Riva et al., 2000). The oral bioavailability of CI-994 in preclinical 
species was 100% (Riva et al., 2000). In a phase 1 study in cancer patients following oral 
dosing (5-15 mg/m2), CI-994 showed rapid absorption (tmax 0.7-1.6 h), oral CL ranging 
between ~30-48 ml/min/m2), dose proportional increases in Cmax and AUC, and moderately 
long t1/2 (7.4-14 h) (Prakash et al., 2001). In the same study, no food effects were observed on 
the oral PK of CI-994. 
4.3 Entinostat (MS-275) 
Entinostat (MS-275) is a small molecule, synthetic benzamide that is currently in phase 2 
trials (Mercurio et al., 2010). It is moderately lipophilic (LogD= 1.79), with moderate plasma 
protein binding (fraction unbound [fu] ranged between 0.375 to 0.439 in preclinical species, 
and 0.188 in humans) (Hooker et al., 2010; Acharya et al., 2006). In preclinical pharmacology 
studies, the tmax of Entinostat ranged between 30-40 minutes with a t1/2 of ~ 1 h in rats, mice 
and dogs, and the oral bioavailability was high (F~ 85%) (Ryan et al., 2005). In a 
radiolabeled tissue distribution and brain penetration study in baboons, radioactivity was 
cleared both by renal and biliary systems, and showed poor brain penetration (Hooker et al, 
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2010). The authors concluded that PgP mediated efflux was probably not the main 
mechanism for the poor brain penetration. 
The clinical PK of Entinostat, in cancer patients, was characterized by variable absorption 
rates (tmax ranged between 0.5 to 60 h), a mean terminal elimination half-life of ~ 52 h, low 
oral clearance (CL/F=17.4 L/h/m2), nearly dose proportional increase in exposures with 
dose (range 2-12 mg/m2), and with substantial interpatient variability (Ryan et al., 2005). 
The nearly 50 fold longer t1/2 in humans was not predicted based on the preclinical PK 
(Ryan et al., 2005). The possible reasons for the extended t1/2 in humans were attributed to 
entero-hepatic recirculation and higher binding to human plasma proteins to some extent 
(Ryan et al., 2005). In an in vitro study, no metabolites could be detected after incubation of 
MS-275 in human liver microsomes, indicating that hepatic metabolism was a minor 
pathway of elimination in humans (Acharya et al., 2006). 
5. Hydroxamic acids 
5.1 Vorinostat (suberoylanilide hydroxamic acid [SAHA], ZOLINZA
TM
) 
Vorinostat (SAHA, ZOLINZATM), belonging to the hydroxamic acid class, was the first 
HDACi to be clinically approved for the treatment of refractory cutaneous T-cell lymphoma 
(Mann et al., 2007). Vorinostat (Mw=264) is poorly soluble in aqueous solutions ~ 191 µg/mL 
[~0.7 mM] (Cai et al., 2010), has a pKa of 9.2 and a LogP ~1.0 (http://www.accessdata.fda). 
It was moderately permeable in Caco-2 cell permeability assays (~ 2 X 10-6 cm/sec), based 
on which, and its poor solubility, it was classified as a Biopharmaceutical Classification 
System (BCS) class 4 drug (http://www.accessdata.fda). It displayed low to moderate 
binding to plasma proteins, with mean PPB of 71.3, 62.5, 43.6, 32.4, and 31.1 % in human, 
rabbit, dog, rat and mouse plasma, respectively (http://www.accessdata.fda). The mean 
blood-to-plasma partition ratio was 1.2, 0.7, and 2.0 in rat, dog and human blood, 
respectively (http://www.accessdata.fda). In in vitro metabolism studies, using S9 and liver 
microsomal fractions from rat, dog and humans, the major metabolic pathway was O-
glucoronidation of Vorinostat in all the 3 species, and a minor pathway was the hydrolysis 
of parent to 8-anilino-8-oxooctanoic acid (8-AOO) (http://www.accessdata.fda). In 
metabolism studies with hepatocytes from rat, dog and humans, the major metabolites 
formed in all the 3 species were 4-anilino-4-oxobutanoic acid (4-AOB, β-oxidation product) 
and 8-AOO (hydrolysis). In dog hepatocytes, the O-glucoronide was also a major 
metabolite, with human hepatocytes generating small amounts of it 
(http://www.accessdata.fda). The CYP450 enzymes were not responsible for the 
biotransformation of Vorinostat (http://www.accessdata.fda). 
In preclinical studies in rats and dogs (Sandhu et al., 2007), the PK of Vorinostat was 
characterized by high systemic CL (7.8 and 3.3 L/h/kg in dog (> liver blood flow of ~ 1.9 
L/h/kg) and rat (=liver blood flow of 3.3 L/h/kg), respectively), low to moderate Vss (1.6 
and 0.6 L/kg in dog and rat respectively), short half-lives (12 min in dog and rat), and poor 
oral bioavailability (11 % and ~ 2% in dog and rat, respectively). The O-glucoronide and 4-
AOB metabolites of Vorinostat were detected in significant levels in both the species 
following oral dosing (AUC ratio of O-glucoronide to Vorinostat was ~ 1.0 and 2.3 in dog 
and rat, respectively; and the AUC ratio of 4-AOB to Vorinostat was 10 and 23 in dog and 
rat, respectively). In excretion studies with radiolabeled Vorinostat, 89-91% and 68-81% of 
the total dose was recovered in urine of rat and dog, respectively. The major metabolites in 
rat urine (over a period of 24 h) were acetaminophen-O-sulfate (~16-19%), 4-AOB (47-48%), 
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6-anilino-oxohexanoic acid (6-AOB) (~10-14%), O-glucoronide in trace amounts, and the 
parent accounting for 0.7- 5%. In dog urine, the major metabolites found were 4-AOB (31-
34%), ortho-hydroxyaniline O-sulfate (17-21%), with minor amounts of the O-glucoronide 
and carnitine esters of 6-AOH and 8-AOO. Thus, Vorinostat was primarily cleared by 
metabolism and renally excreted in rat and dog. The data suggest that the low 
bioavailability of Vorinostat in rat and dog was due to a high first-pass effect and not due to 
absorption since the > 90% of the dose was recovered in urine, indicative of high intestinal 
absorption (fraction of dose absorbed [Fa]=0.8-1.0) (Sandhu et al., 2007).  
Vorinostat did not inhibit any of the major human CYP450 enzymes 
(http://www.accessdata.fda). It did not significantly induce CYP1A2, 2B6, 2C9, 2C19 and 
3A4 in freshly cultured human hepatocytes, although the induction activity of 2C9 and 2C19 
were suppressed at the highest concentration (http://www.accessdata.fda). 
In the first clinical trial in cancer patients Vorinostat was administered intravenously as a 2 h 
infusion (Kelly et al., 2003). The intravenous route was chosen due to predictions of poor 
oral bioavailability based on its preclinical ADME properties (Kelly et al., 2003). In a 
subsequent phase 1 trial, Vorinostat was dosed orally in patients with advanced cancer in 
which the oral PK was also characterized (Kelly et al., 2005). Vorinostat showed dose 
proportional increase in Cmax and AUC following single oral doses of 100, 400 and 600 mg, 
with the average terminal t1/2 ranging between ~ 92 to 127 minutes, median tmax ranging 
between 53 to 150 minutes, and an absolute oral bioavailability of 43%. No apparent changes 
were observed in PK following multiple oral dosing. The t1/2 following oral dosing was 
longer than the t1/2 observed after i.v. dosing (range of ~35-42 min), suggesting that the 
elimination of Vorinostat was absorption rate limited (Kelly et al., 2005). In another study 
investigating the PK of Vorinostat, at 400 mg, and its major metabolites in cancer patients, 
the mean serum exposures of the O-glucoronide and 4-AOB were 3-4 fold and 10-to-13 fold 
higher, respectively, than that of Vorinostat (Rubin et al., 2006). In the same study, up to 
18% and 36% of the O-glucoronide and 4-AOB, respectively, were recovered in urine, with 
the parent accounting for < 1 % of the total dose, clearly indicating that Vorinostat was 
cleared primarily by metabolism in humans, and that the O-glucoronide and 4-AOB were 
the major metabolites. The main enzymes responsible for the formation of the O-
glucoronide were identified as the UDP-glucoronosyltransferases (UGTs), such as the UGTs 
2B17 and 1A9, which are expressed in the liver, and the extrahepatic UGTs 1A8 and 1A10 
(Balliet et al.,2009). UGT2B17 was one of the major enzymes contributing to the formation of 
the O-glucoronide of Vorinostat in humans (Balliet et al., 2009). Since UGTs are known to 
show extensive polymorphism, including UGT2B17, they have been associated with the 
variable PK and response of Vorinostat in patients (Balliet et al., 2009). 
There have been no reports on allometric scaling or the predictions of human PK based on 
preclinical ADME data so far. 
5.2 Panabinostat (LBH589) 
Panabinostat (LBH589) is a cinnamic hydroxamic acid and a potent pan HDAC inhibitor 
that is currently in phase 2 clinical trials (Mercurio et al., 2010). Very little information is 
available on its preclinical ADME characteristics. It showed poor oral bioavailability in 
rodents (F=6% in rats) and moderate F in dogs (33-50%) (Konsoula et al, 2009).  
Like SAHA, Panabinostat was first tried as an intravenous formulation in the phase 1 
clinical trials (Giles et al., 2006). In that study, LBH589 showed dose proportional increase in 
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Cmax and AUC between 4.8 and 14 mg/m2, with the terminal half-life ranging between 8-16 
h. The Vss and CL were not reported. The oral PK of Panabinostat was characterized by 
rapid absorption (tmax =1-1.5 h), linear increase in dose between 20 and 80 mg and the 
terminal t1/2 ranged between 16-17 h (Prince et al, 2009). In an oral mass-balance study in 
patients with advanced cancer, following a single oral dose of 20 mg of 14C radioactively 
labeled Panabinostat, 87% of the administered dose was recovered in the excreta, with 
unchanged drug accounting for <3% of the administered dose in the feces, suggesting good 
oral absorption and extensive metabolism (Clive et al, 2006). The major circulating 
metabolites were glucoronidation products of Panabinostat, in addition to hydrolysis and 
reduction products. Thus, it appears that there is no single major metabolic pathway for the 
elimination of Panabinostat in humans. CYP3A4 does not significantly contribute to the 
elimination of Panabinostat in humans (DeJonge et al, 2009). Human PK data suggest that 
Panabinostat is a permeable drug and the poor bioavailability in preclinical rodents could be 
due high first-pass and poor solubility. 
5.3 Givinostat (ITF2357) 
Givinostat (ITF2357) is a pan HDAC inhibitor, belonging to the hydroxamic acid class that is 
currently in phase 2 trials for many hematological malignancies (Mercurio et al., 2010). 
Preclinical ADME information is either limited or qualitative for Givinostat. Metabolism 
was the primary clearance mechanism in preclinical species like rats, dogs, rabbits and 
monkeys, with excretion being biliary or renal (Furlan et al, 2011). In a phase 1 study in 
healthy volunteers, the oral PK of Givinostat was characterized by rapid absorption, dose 
proportional increases in Cmax and AUC upon single and multiple oral dosing, and the 
terminal half-life ranged between 5-7 h (Furlan et al, 2011). Two major circulating 
metabolites of Givinostat, a carboxylate and an amide formed due to oxidation and 
reduction of the hydroxamic acid group, were detected at significant levels in plasma.  
5.4 Belinostat (PXD101) 
Belinostat (PXD101) is a hydroxamic acid class potent pan HDAC inhibitor that is currently 
in phase 2 clinical trials (Mercurio et al., 2010). It is a small molecule (Mw 318) and sparingly 
soluble in aqueous solutions (Urbinati et al., 2010). Preclinical ADME information on 
Belinostat is limited. Preclinical pharmacodynamic studies in mice (Plumb et al., 2003) and 
PK studies in non-human primates (Warren et al 2008) have been performed using IV 
administrations, suggesting that Belinostat may have poor solubility and bioavailability 
issues. However, in dogs an oral bioavailability of 30-35% was reported (Steele et al, 2011). 
In rhesus monkeys, clearance was rapid (425 mL/min/m2) with a t1/2 of 1.0 h (Warren et al 
2008). In a PK/PD study in mice following IV dosing at 200 mg/kg, Belinostat declined 
rapidly in plasma (ca t1/2 ~ 0.4 h), suggesting high systemic clearance (Marquard et al 2008). 
In the same study a correlation was observed between tumor concentrations and histone 4 
acetylation levels indicating that Belinostat penetrated solid tumors.  
In a phase 1 clinical study in patients with solid tumors, where Belinostat was administered 
as a 30 min IV infusion, its PK was characterized by dose proportional increase in AUC and 
Cmax, and a short t1/2 (0.45 to 0.79 h) (Steele et al., 2008). The oral PK of Belinostat following a 
1000 mg/m2 dose in patients with solid tumors, was characterized by mean tmax of 1.9 h 
(although the oral concentration-time profile showed a flat absorption phase), with a mean 
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t1/2 of 1.5 h (Steele et al, 2011). High variability was observed in oral clearance (39-71%) due 
to which dose proportionality analysis was not attempted. The oral t1/2 was longer than that 
of the IV, which was attributed to a slow absorption rate (Steele et al., 2011). Oral 
bioavailability ranged between low to moderate (20-50%) in patients with advanced solid 
tumors (Kelly et al., 2007). Although a correlation between H4 acetylation and 
concentrations was observed following oral dosing at 1000 mg/m2 (Steele et al., 2011), recent 
phase 2 trials have employed IV dosing of Belinostat (Cashen et al., 2011). In another Phase 1 
study, where the metabolism of Belinostat was studied in patients with hepatocellular 
carcinoma, five metabolites were identified (Wang et al, 2010). Glucoronidation was the 
most significant pathway of metabolism, and the methylated and amide (reduction of 
hydroxamic acid) products were also detected. The acid and N-glucoside forms of Belinostat 
were found as minor metabolites. In an in vitro assay using 12 isoforms forms of human 
UGTs, Belinostat was mainly cleared by UGT1A1 (Wang et al., 2010). The data taken 
together suggest that Belinostat was primarily cleared by phase 2 metabolism, involving 
UGT1A1, in humans. 
5.5 CUDC-101 
CUDC-101 is a small molecule (Mw 434.5) hydroxamic acid HDACi, synthesized by 
incorporating the hydroxamic acid group into the epidermal growth factor receptor (EGFR) 
pharmacophore, that exhibited antiproliferative effects in vitro and in vivo (Cai  et al., 2010; 
Lai et al, 2010). The preclinical ADME of CUDC-101 is not available (Cai et al., 2010). The 
fact that CUDC-101 was dosed IV in the preclinical efficacy studies suggests that it may 
have had poor oral bioavailability (Cai et al., 2010). CUDC-101 is currently in phase 1 trials 
(Cai et al., 2010) 
5.6 JNJ-26481585 
JNJ-26481585 is a second-generation, small molecule hydroxamic acid based potent pan-
HDACi that is currently in phase 1 trials (Mercurio et al., 2010).  The preclinical ADME 
information for this compound is minimal. JNJ-26481585 has been shown to undergo 
extensive first-pass metabolism resulting in poor oral bioavailability in rodents, due to 
which it had to be dosed intraperitoneally (IP) in xenograft models (Arts et al., 2009). In a 
phase 1 oral PK/PD study in solid tumor patients, the exposures of JNJ-26481585 (dosed q.d. 
in 3 weekly cycles) increased dose proportionally between 2 and 12 mg (Postel-Vinay et al., 
2009). In the same study promising antitumor activity was observed indicating orally active 
exposures were achieved in humans. 
5.7 CRA-024781(PCI-24781) 
CRA-024781(PCI-24781) is a small molecule, hydroxamic based pan HDACi that is currently 
in phase 1 trials (Mercurio et al., 2010). In preclinical murine models of efficacy, its PK was 
characterized by a very short t1/2 (~ 7 min), very high CL (~ 18 L/h/kg) and high Vss (~ 9 
l/kg) (Buggy et al., 2006). It was administered intravenously at high doses of up to 200 
mg/kg in the efficacy models, most probably owing to poor oral bioavailability and high CL 
(Buggy et al, 2006). In a phase 1 study in patients with solid tumors, where PCI-24781was 
dosed as a 2 h IV infusion, the mean elimination t1/2 was ~ 6 h, high CL and moderately high 
Vss, low oral bioavailability of 28%, with the carboxylic acid and amide metabolites formed 
at ~ 60 %  of the parent (Undevia et al., 2008). 
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5.8 Pracinostat (SB939) 
Pracinostat (SB939) is a hydroxamic acid based potent HDACi that is in multiple phase 2 
clinical trials (http://clinicaltrials.gov/ct2/results?term=Sb939) in patients with solid 
tumors and hematological malignancies. Since the clinically advanced hydroxamic acid 
HDACi (Zolinza, Panabinostat and Belinostat) had ADME liabilities, such as poor solubility 
and oral bioavailability, we sought to identify a candidate that would achieve 
pharmacologically active exposures in humans when dosed orally. Pracinostat is a small 
molecule (Mw 359) moderately lipophilic base (LogD7.4 =2.1) with high aqueous solubility 
(>100 mg/mL in water for the HCl salt of SB939) and high permeability with low efflux 
which indicated that Pracinostat would show high intestinal absorption in vivo (Wang et al., 
2011). Based on its solubility and permeability Pracinostat was categorized as a BCS class 1 
compound (S*BIO Data files). In preclinical PK studies Pracinostat showed higher oral 
bioavailability in mice (F=34%) and dogs (F=65%), than Zolinza, Panabinostat and Belinostat 
(table 2). The superior efficacy of Pracinostat, over Zolinza and Belinostat, when dosed 
orally in murine xenograft models was consistent its improved PK profile (Novotny-
Diermayr et al., 2011). Pracinostat was found to selectively accumulate in tumors which 
correlated well with increased and prolonged acetylation levels in tumor which, in turn 
correlated with high tumor growth inhibition in mice (Novotny-Diermayr et al., 2011).  
Preclinical ADME of Pracinostat was characterized by: a) in in vitro liver microsomal 
stability studies, Pracinostat was most stable in human and dog, moderate in mouse, and 
least stable in rat; b) uniform PPB of 84-94% in preclinical species and humans; c) was 
metabolized mainly by human CYP3A4 and 1A2; d) did not inhibit the major human CYPs 
except moderate inhibition of 2C19 (~ 6 µM); e) lack of significant induction of human 
CYP3A4 and 1A2 in vitro; f) metabolite identification studies using liver microsomes showed 
the formation of N-deethylation and bis-N-deethylation as major metabolites in addition to 
minor oxidative products; g) a glucoronidation product of SB939 was found as the major 
metabolite in rat urine following oral dosing; h) PK: high systemic clearance of 9.2, 4.5 and 
1.5 L/h/kg in mice, rat and dog, respectively and high volume of distribution (Vss ranged 
between 1.7 to 4.2 L/kg) in preclinical species; i) moderate F in mice and dogs and poor in 
rats (Jayaraman et al., 2011). In PK/PD studies in HCT116 xenograft models, studying the 
relationship between tumor growth inhibition and the PK/PD indices such as 
AUC/IC50,HCT116, Cmax/ IC50,HCT116, and time above IC50,HCT116, Pracinostat was found to have 
the highest PK/PD ratios for all the three PK/PD parameters when compared to Vorinostat, 
Panabinostat and Belinostat (figure 1) (Jayaraman et al., 2009).  
Pracinostat showed linear allometric relationships for Vss and CL in preclinical species. 
Prediction of human PK parameters using allometry indicated oral exposures would be 
achieved in humans with an acceptable t1/2 which, was subsequently found to be consistent 
with the observed data from cancer patients (Jayaraman et al., 2011). The human PK of 
Pracinostat was simulated with the Simcyp ADME simulator (Jamei et al., 2009) using the 
physico-chemical and in vitro ADME data. The simulated PK profiles were in good 
agreement with the observed mean data, and the mean oral clearance and AUCs were 
predicted reasonably well (within 2 fold of observed data) (Jayaraman et al., 2011). 
Furthermore, simulations of drug-drug interactions (DDI) of Pracinostat in humans with the 
potent CYP3A inhibitor and inducers, ketoconazole and rifampicin, respectively, and with 
omeprazole (substrate of 2C19) showed lack of potential DDI at the clinically relevant dose 
of 60 mg (Jayaraman et al., 2011). 
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Fig. 1. The relationship between tumor growth inhibition (%TGI) and PK/PD parameters for 
HDACi in the murine HCT116 xenograft model (Jayaraman et al., 2009). a) AUC/IC50, HCT116; 
b) Cmax/ IC50, HCT116 ; c) time above IC50, HCT116. 
 
 
Parameter 
mice dog 
Pracinostat
(SB939) 
Vorinostat 
(SAHA) 
Belinostat
(PXD101)
Panabinostat 
(LBH589) 
Pracinostat 
(SB939) 
Vorinostat 
(SAHA) 
Cmax(ng/mL) 2632 501 489 116 1537 35 
tmax(h) 0.17 0.5 0.17 0.17 0.8 0.7 
t1/2(h) 2.4 0.75 1.3 2.9 4.1 0.2 
AUC0-inf 
(ng.h/mL) 
1841 619 287 126 4481 55 
F (%) 34 8.3 6.7 4.6 65 2 
Table 2. Comparison of preclinical pharmacokinetics of Pracinostat with that of other 
advanced hydroxamic acid HDACi. 
In the first phase 1 study in patients with solid tumors, Pracinostat showed rapid absorption 
(tmax = 0.9-2 h), dose proportional increase in Cmax and AUC between 10 and 60 mg doses, a 
mean terminal t1/2 of ~ 7 h, and lack of significant accumulation on repeated dosing (Yong et 
al, 2011). In the same study, pharmacologically active concentrations were achieved at the 
starting dose of 10 mg, and a dose dependent increase in histone acetylation was observed. 
At the 60 mg dose high acetylation levels was observed in all patients indicating sustained 
target inhibition, and two of the patients experienced prolonged disease stabilization. The 
clinical PK of Pracinostat was superior to the other hydroxamic acid HDACi in the clinic 
(table 3). The high aqueous solubility, permeability, good oral bioavailability and 
predictable human PK of Pracinostat contributed to obtaining active exposures in the clinic 
when dosed orally, which was in contrast to the intravenous dosing of Zolinza, Panabinostat 
and Belinostat in the initial clinical trials. The terminal t1/2 of Pracinostat was longer than 
that of Zolinza and Belinostat, and shorter than Panabinostat.  
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In summary, the superior preclinical ADME of Pracinostat over Zolinza, Panabinostat and 
Belinostat was translated into the clinic.  
 
Parameter 
Pracinostat 
(SB939)* 
Vorinostat 
(SAHA)# 
Panabinostat 
(LBH589)% 
Belinostat 
(PXD101)$ 
Dosage regimen thrice weekly once daily thrice weekly once daily 
Recommended 
Dose (mg) 
60 400 20 250 
t1/2(h) 7-9 0.8-3.9 16 1.5 
AUC0-
inf(ng.h/mL) 
1226(3.4µM) 1716 (6.5 µM) 183(0.54 µM) 2767 (8.7 µM) 
Remarks 
Orally active 
exposures 
achieved at 
FTIM&. Best-in-
class profile. 
FTIM dose was 
given IV due to 
poor F in preclinical 
species. 
FTIM dose was 
given IV due to 
poor F in 
preclinical 
species. Limited 
exposure. 
FTIM dose was 
given IV due to 
poor F in 
preclinical 
species. Poor 
PK/PD 
* Yong et al., 2011 
# Rubin et al., 2006 
% Prince et al., 2009 
$ Steele et al., 2011 
& first time in Man 
Table 3. Comparison of oral clinical pharmacokinetics of Pracinostat with hydroxamic acid 
HDAC inhibitors 
6. Conclusions 
The clinical use of the less potent short chain fatty acid HDACi (PB, SP and sodium 
valproate) in cancer patients was limited by the requirement of high doses and short half-
life. The cyclic peptide drug Depsipeptide had to be administered intravenously because of 
poor solubility and oral bioavailability. The most clinically advanced hydroxamic acid 
HDACi such as Zolinza, Belinostat and Panabinostat were initially administered IV in 
patients owing to their poor solubility and oral bioavailability in preclinical species. 
Formulations were subsequently developed for oral administration. We succeeded in 
designing the hydroxamic acid pan HDACi Pracinostat (SB939) which had high solubility 
and permeability, with superior preclinical ADME and PK/PD properties when compared 
to the other hydroxamic acid HDACi, which subsequently helped to achieve 
pharmacologically active exposures upon oral dosing in cancer patients. 
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